Misplaced Pages

Idursulfase: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 09:32, 1 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'ChEMBL').← Previous edit Latest revision as of 05:34, 18 August 2024 edit undoCharles Matthews (talk | contribs)Autopatrolled, Administrators360,392 edits wording 
(20 intermediate revisions by 17 users not shown)
Line 1: Line 1:
{{Drugbox {{Drugbox
| Verifiedfields = changed | Verifiedfields = changed
| verifiedrevid = 413661956 | verifiedrevid = 458433866
| IUPAC_name = | IUPAC_name =
| image = | image =
⚫ <!-- Clinical data -->

⚫ <!--Clinical data-->
| tradename = | tradename =
| Drugs.com = {{drugs.com|monograph|idursulfase}} | Drugs.com = {{drugs.com|monograph|idursulfase}}
Line 11: Line 10:
| pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = | pregnancy_category =
| licence_EU = yes
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
Line 17: Line 17:
| legal_status = | legal_status =
| routes_of_administration = | routes_of_administration =
⚫ <!-- Pharmacokinetic data -->

⚫ <!--Pharmacokinetic data-->
| bioavailability = | bioavailability =
| protein_bound = | protein_bound =
Line 24: Line 23:
| elimination_half-life = | elimination_half-life =
| excretion = | excretion =
⚫ <!-- Identifiers -->

⚫ <!--Identifiers-->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = NA | ChemSpiderID = none
| CAS_number_Ref = {{cascite|correct|??}} | CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50936-59-9 | CAS_number = 50936-59-9
Line 33: Line 31:
| ATC_suffix = AB09 | ATC_suffix = AB09
| PubChem = | PubChem =
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01271 | DrugBank = DB01271
| UNII_Ref = {{fdacite|changed|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5W8JGG2651 | UNII = 5W8JGG2651
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04499 | KEGG = D04499
| ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = <!-- blanked - oldvalue: 1201826 --> | ChEMBL = 1201826
<!-- Chemical data -->
| chemical_formula = | chemical_formula =

| molecular_weight = | molecular_weight =
}} }}
'''Idursulfase''' (brand name '''Elaprase''') is a drug used to treat ] (also called ] II).<ref name="pmid17459751">{{cite journal |author=Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC |title=Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II |journal=Mol. Genet. Metab. |volume=91 |issue=2 |pages=183–90 |year=2007 |pmid=17459751 |doi=10.1016/j.ymgme.2007.03.003}}</ref> It is a purified form of the ] ] ] and is produced by ] in a human cell line. '''Idursulfase''' (brand name '''Elaprase'''), manufactured by ], is a drug used to treat ] (also called ]).<ref name="pmid17459751">{{cite journal |vauthors=Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC |title=Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II |journal=Mol. Genet. Metab. |volume=91 |issue=2 |pages=183–90 |year=2007 |pmid=17459751 |doi=10.1016/j.ymgme.2007.03.003}}</ref> It is a purified form of ], a ] enzyme, and is produced by ] in a human cell line.

⚫ It is one of the most expensive drugs ever produced, costing $375,000 per year.<ref>{{cite news |url=http://www.mediadoctor.ca/content/article.jsp?intArticleID=293 |title=Drug approved to treat rare but potentially deadly disease |accessdate=2011-04-29 |format= |work=}}</ref><ref>, Matthew Herper, Forbes, Feb. 22, 2010</ref>


⚫ It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.<ref>{{cite news |url=http://www.mediadoctor.ca/content/article.jsp?intArticleID=293 |title=Drug approved to treat rare but potentially deadly disease |access-date=2011-04-29 |archive-url=https://web.archive.org/web/20110224123252/http://www.mediadoctor.ca/content/article.jsp?intArticleID=293 |archive-date=2011-02-24 |url-status=dead }}</ref><ref>, Matthew Herper, Forbes, Feb. 22, 2010</ref><ref>, Barbara Kollmeyer, Marketwatch, Fed. 3, 2016</ref>
It is manufactured by ].


==References== ==References==
Line 58: Line 54:


{{Other alimentary tract and metabolism products}} {{Other alimentary tract and metabolism products}}

] ]
]




{{gastrointestinal-drug-stub}} {{gastrointestinal-drug-stub}}

]
]
]
]
]

Latest revision as of 05:34, 18 August 2024

Pharmaceutical compound
Idursulfase
Clinical data
AHFS/Drugs.comMonograph
License data
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
  (what is this?)  (verify)

Idursulfase (brand name Elaprase), manufactured by Takeda, is a drug used to treat Hunter syndrome (also called MPS-II). It is a purified form of iduronate-2-sulfatase, a lysosomal enzyme, and is produced by recombinant DNA technology in a human cell line.

It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.

References

  1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751.
  3. "Drug approved to treat rare but potentially deadly disease". Archived from the original on 2011-02-24. Retrieved 2011-04-29.
  4. Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
  5. , Barbara Kollmeyer, Marketwatch, Fed. 3, 2016

External links

Other alimentary tract and metabolism products (A16)
Amino acids and derivatives
Enzymes
Other


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it.

Categories: